BioAge Labs (NASDAQ:BIOA) Earns Buy Rating from Analysts at Needham & Company LLC

Needham & Company LLC assumed coverage on shares of BioAge Labs (NASDAQ:BIOA) in a report issued on Friday morning, MarketBeat reports. The firm issued a buy rating and a $50.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Piper Sandler began coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Citigroup lifted their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Oppenheimer assumed coverage on BioAge Labs in a report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Morgan Stanley set a $23.00 price objective on BioAge Labs in a research note on Wednesday, February 4th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BioAge Labs currently has an average rating of “Moderate Buy” and a consensus price target of $46.25.

BioAge Labs Price Performance

BIOA opened at $16.15 on Friday. The company has a market cap of $716.74 million, a P/E ratio of -7.21 and a beta of 1.21. The firm’s 50-day moving average price is $19.88 and its 200-day moving average price is $13.08. BioAge Labs has a 52-week low of $2.88 and a 52-week high of $24.00.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Tuesday, March 24th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. The company had revenue of $3.08 million during the quarter. BioAge Labs had a negative net margin of 896.11% and a negative return on equity of 27.86%.

Insider Buying and Selling at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 7,433 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the transaction, the chief executive officer owned 976,949 shares of the company’s stock, valued at $17,702,315.88. The trade was a 19.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 267,540 shares of company stock valued at $4,895,168. 20.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BIOA. Police & Firemen s Retirement System of New Jersey acquired a new position in BioAge Labs in the second quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs during the 3rd quarter worth approximately $27,000. CWM LLC grew its stake in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after purchasing an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of BioAge Labs during the 2nd quarter valued at approximately $60,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.